✨ Free AI Report
CareDx, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research CareDx, Inc.
Company Research

CareDx, Inc.: Business Overview, Financials & Competitive Analysis

CareDx, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). CareDx is a market-leading transplant diagnostics company expanding into specialty oncology with improving profitability guidance and strategic portfolio optimization. Market-leading position in transplant genomics with diversification into oncology and cell therapy provides runway. However, divesting the lab products business and pending Naveris acquisition signal portfolio repositioning that carries execution risk.

What is CareDx, Inc.'s industry? CareDx, Inc. (caredx.com) operates in In-Vitro Diagnostics. AskCyborg classifies CareDx, Inc. under In-Vitro Diagnostics in its company registry.

CareDx is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company is ...

7/ 10Strong

Cyborg Score thesis

CareDx is a market-leading transplant diagnostics company expanding into specialty oncology with improving profitability guidance...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
5 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest CareDx, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for CareDx, Inc.

AskCyborg analysts argue the bull and bear cases for CareDx, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
CareDx, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

CareDx, Inc. Overview

Pro stress-test →

CareDx is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company is the leading provider of genomics-based information for transplant patients, with commercially available testing services including AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung for transplant monitoring.

Strategic Profile

Pro stress-test →

CareDx generates the majority of revenue from testing services, and as of June 2026 had trailing 12-month revenue of $458M. In April 2026, CareDx entered a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million, enabling focus on high-margin transplant diagnostics and expansion into oncology and cell therapy applications.

Competitive Landscape

Pro stress-test →

CareDx is the leading provider of genomics-based information for transplant patients. The transplant diagnostics market includes niche genomics and molecular testing competitors. Veracyte is a VC-backed competitor in this space. CareDx differentiates through proprietary donor-derived cell-free DNA (dd-cfDNA) assays and integrated digital workflows for transplant centers, with expansion into specialty oncology providing additional competitive moats.

Industry Context

CareDx, Inc. operates in In-Vitro Diagnostics.

Key facts

Founded: 1998 · Headquarters: Brisbane, California, US · Revenue: $458M (trailing 12-month as of Q2 2026); 2026 full-year guidance: $490–$500M

What the analysts stress-tested

The top findings that survived the multi-agent debate for CareDx, Inc..

  • CareDx acquired 10 companies including Naveris (for cancer minimal residual disease surveillance testing) and made 3 strategic investments including Miromatrix, signaling expansion into specialty oncology and next-generation transplant diagnostics applications.

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Announced agreement to divest Lab Products business to EuroBio Scientific for $170 million
Get alerted when CareDx, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

VeracyteGenomics-based molecular diagnostics for cancer and transplant monitoring→TharosDonor-derived cell-free DNA testing for transplant monitoring→NateraGenomic testing company offering transplant rejection monitoring→Genomic LifePrecision diagnostics for transplant assessment→EurofinsClinical diagnostics laboratory services including transplant testing→

Compare CareDx, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

CareDx, Inc. operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about CareDx, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare CareDx, Inc. and its top competitor on Cyborg Score”
“What did CareDx, Inc. do this quarter?”
“Is CareDx, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does CareDx, Inc. do?+
CareDx is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. The company is ...
What is CareDx, Inc.'s Cyborg Score?+
CareDx, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are CareDx, Inc.'s main competitors?+
Named competitors include Veracyte, Tharos, Natera, Genomic Life. The full competitive landscape is in the AskCyborg report.
How can I get the full CareDx, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the CareDx, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track CareDx, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA8Veracyte, Inc.8Natera, Inc.